There is a considerable amount of evidence that supports the possibility of an increased risk
of pneumonia associated with prolonged use of inhaled corticosteroids (ICS) in patients …

… , but risk increases with high-dose ICSs. Although several new drugs are being developed
and … for asthma, but more effective initial controller therapy could be developed for COPD. …

OBJECTIVE: Inhaled corticosteroids (ICSs) are the most effective medications available for
patients with persistent asthma of all severities and currently are recommended as the …

… between the use of inhaled corticosteroids (ICSs) and the risk of developing pneumonia in
patients with chronic obstructive pulmonary disease (COPD). An increased risk of pneumonia …

… development of irreversible airflow obstruction. Careful pathologic studies have shown that
inhaled corticosteroid … proven, that inhaled corticosteroid therapy reduces the risk of asthma …

… to the development of side effects. The amount of an … , the risk of subcapsular and nuclear
cataract development related to ICS use seems minimal in asthmatic children, although the risk …

… A Cox proportional hazard model was used to estimate the risk of lung cancer development
… To assess the potential for effects of bias by indication, we also developed a propensity …

… multiple investigations of the effects of inhaled and oral corticosteroids, used in the treatment
of … development, duration and dose of corticosteroid therapy, and illness severity on the …

… ischaemic heart disease and diabetes, may be at greater risk of developing corticosteroid
side effects, but these may take time to develop and this may be longer than the duration of a …

… development of highly potent, topically active corticosteroids … The beneficial effects of inhaled
corticosteroids in asthma are … risk of being overtaken by improved inhaled corticosteroids …